Bone Biologics Corp — Director's Dealing 2025

Jan 21, 2025

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Bone Biologics Corp (BBLG)
CIK: 0001419554
Period of Report: 2025-01-15

Reporting Person: Frelick Jeff (Chief Executive Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2025-01-15	Employee Stock Option	$0.9678	A	54110	Acquired	2027-01-15	Common Stock (54110)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	2151	Direct

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Employee Stock Option	$3.61	2026-01-17	Common Stock (25000)	25000	Direct
Employee Stock Option	$9540.00	2025-12-27	Common Stock (173)	173	Direct
Employee Stock Option	$12300.00	2026-05-26	Common Stock (44)	44	Direct
Employee Stock Option	$57.60	2025-01-25	Common Stock (157)	157	Direct

Footnotes

F1: This option was granted under the Bone Biologics Corporation 2015 Equity Incentive Plan, in a transaction exempt under Rule 16b-3 and, except as otherwise provided in the award notice,vests and becomes exercisable immediately.

F2: This option is fully vested as of the date of this report.